Development and Evaluation of Adeno-HTLV-III Hybrid Virus and Non-Cytopathic HTLV-III Mutant for Vaccine Use.
Abstract
Acquired immunodeficiency disease syndrome (AIDS) was initially recognized as a separate disease in 1981. Results from research groups in France and the United States determined that a previously unknown virus called HIV is the primary aetiological agent of AIDS. Two HIV vaccines, a recombinant Adeno-HIV hybrid virus and a recombinant vaccinia HIV will be tested. The recombinant Adeno-HIV virus is being developed as part of this proposal. The vaccines will be tested in two species of monkeys, chimpanzees and African green monkeys. Vaccinated animals will be challenged with a defined dose of HIV virus. Assessment of vaccine efficacy against the virus challenge will include T4/T8 ratios, Interleukin-2 production, HTLV-III serology and ability to detect infectious HTLV-III virus in peripheral blood cells. T-cell mediated immunity will be assessed by monitoring cytotoxic T cell activity and antigen-induced PBL proliferation. In Phase II of this proposal, we will focus on whether generation and cloning of HIV specific killer T cells could be used to protect humans from AIDS. Keywords: DNA recombinant, Antibody, T-cell.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 28, 1987
- Accession Number
- ADA189926
Entities
People
- Martha T. Lubet
- Sandra K. Dusing